CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicion, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea.
² Department of Thoracic and Cardiovascular Surgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea.

Editorial

Der Sheng Sun et al. J Thorac Dis. 2019 Mar.

. 2019 Mar;11(Suppl 3):S394-S395.

doi: 10.21037/jtd.2018.12.02.

¹ Division of Medical Oncology, Department of Internal Medicion, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea.
² Department of Thoracic and Cardiovascular Surgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. Janjigian YY, et al. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.

1. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol 2015;33:1760-9. 10.1200/JCO.2014.60.1799 - DOI - PubMed
1. NCCN Guidelines for Patients 2018, Esophageal Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
1. Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013. 10.1001/jamaoncol.2018.0013 - DOI - PMC - PubMed
1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-71. 10.1016/S0140-6736(17)31827-5 - DOI - PubMed
1. Walsh EM, Kelly RJ. Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction. J Thorac Dis 2018;10:1308-13. 10.21037/jtd.2018.03.43 - DOI - PMC - PubMed